557 patients included in the ITT efficacy analysis 555 assessed for EGFR expression

1. 1861 patients screened 1688 with tumors suitable for EGFR expression assessment 321 excluded 183 did not meet inclusion criteria 79 refused to participate 59 other reasons 1442 patients with EGFR-expressing tumors 4 EGFR status unknown 1125 randomly assigned ITT population 557 allocated to chemotherapy plus cetuximab 548 given chemotherapy plus cetuximab 6 not given study treatment 3 given chemotherapy alone 568 allocated to chemotherapy alone 559 given chemotherapy 9 not given study treatment 543 discontinued study 372 progressive disease 74 died 15 withdrew consent 14 symptomatic deterioration 10 further anticancer treatment needed 56 other 2 lost to follow-up 563 discontinued study 350 progressive disease 58 died 13 withdrew consent 16 symptomatic deterioration 18 further anticancer treatment needed 100 other 8 lost to follow-up • 557 patients included in the ITT efficacy analysis • 555 assessed for EGFR expression • 482 assessed for EGFR mutation status • 481 assessed for both EGFR expression and EGFR • mutation status • 568 patients included in the ITT efficacy analysis • 566 assessed for EGFR expression • 489 assessed for EGFR mutation status • 489 assessed for both EGFR expression and EGFR • mutation status High EGFR expression 115 EGFR wild-type 25 EGFR mutant High EGFR expression 123 EGFR wild-type 25 EGFR mutant Low EGFR expression 307 EGFR wild-type 42 EGFR mutant Low EGFR expression 292 EGFR wild-type 41 EGFR mutant